Loading...

MedXY AI/MedXY News/Tag: oncology

MedXY News

EnglishTag

oncology

85 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

The TIP-CA Model: A Validated Tool to Stratify Cancer Risk in Adult Dermatomyositis Patients

The TIP-CA Model: A Validated Tool to Stratify Cancer Risk in Adult Dermatomyositis Patients

Researchers have developed and validated the TIP-CA model, a clinical tool using five key factors—anti-TIF1-γ, ILD absence, poikiloderma, DM subtype, and anemia—to accurately predict malignancy risk in patients with dermatomyositis, enablin

Section: DermatologyMar 4, 2026

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers

A multicentre cohort study confirms that upfront 30% irinotecan dose reductions for UGT1A1 poor metabolisers effectively prevent severe toxicity without compromising progression-free or overall survival in colorectal and pancreatic cancer p

Section: GastroenterologyMar 4, 2026

Adjunctive Ultrasonography Reduces Advanced Breast Cancer Risk in Women Aged 40-49: Long-Term Evidence from J-START

Adjunctive Ultrasonography Reduces Advanced Breast Cancer Risk in Women Aged 40-49: Long-Term Evidence from J-START

A prespecified secondary analysis of the J-START trial reveals that adding ultrasonography to mammography for women aged 40-49 significantly reduces the long-term cumulative incidence of advanced breast cancer, particularly in populations w

Section: newsMar 2, 2026

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

The Phase 3 KEYNOTE-905/EV-303 trial demonstrates that perioperative enfortumab vedotin plus pembrolizumab significantly improves event-free survival (HR 0.40) and overall survival (HR 0.50) compared to surgery alone in cisplatin-ineligible

Section: newsFeb 23, 2026

Optimizing Prognosis: The New AJCC Version 9 Staging for Salivary Gland Carcinoma

Optimizing Prognosis: The New AJCC Version 9 Staging for Salivary Gland Carcinoma

The proposed AJCC/UICC Version 9 staging for salivary gland carcinoma shifts toward a unified, specific system using lymph node count and extranodal extension, significantly improving prognostic accuracy for both major and minor salivary gl

Section: newsFeb 21, 2026

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif

Section: newsFeb 20, 2026

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer

The phase 3 SONIA trial demonstrates that initiating CDK4/6 inhibitors in the first-line setting does not improve overall survival compared to second-line use in HR-positive, ERBB2-negative advanced breast cancer, while significantly increa

Section: newsFeb 20, 2026

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial

The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit

Section: newsFeb 19, 2026

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i

Section: Hematology-OncologyFeb 19, 2026

Breaking the Cycle of Exclusion: How Cultural Capital and Stigma Hinder Hospice Access for Low-Income Patients

Breaking the Cycle of Exclusion: How Cultural Capital and Stigma Hinder Hospice Access for Low-Income Patients

A qualitative study published in JAMA Network Open identifies how limited cultural capital, cancer-related stigma, and economic deprivation form a self-reinforcing cycle that excludes low-income patients from hospice care, highlighting the

Section: newsFeb 11, 2026

Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer

Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer

A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to d

Section: newsFeb 10, 2026

Opportunistic Bilateral Salpingectomy Reduces Serous Ovarian Cancer Risk by Nearly 80 Percent

Opportunistic Bilateral Salpingectomy Reduces Serous Ovarian Cancer Risk by Nearly 80 Percent

A large-scale population study confirms that removing fallopian tubes during unrelated pelvic surgeries reduces serous ovarian cancer risk by 78%, providing robust evidence for its use as a primary prevention strategy against high-grade ser

Section: newsFeb 10, 2026

Beyond the Bill: Hope and Social Support as Vital Buffers Against Cancer-Related Financial Toxicity

Beyond the Bill: Hope and Social Support as Vital Buffers Against Cancer-Related Financial Toxicity

A multisite study reveals that financial toxicity significantly reduces life satisfaction in cancer patients. However, hopefulness and social support act as critical mediators, suggesting that integrating psychosocial resilience training wi

Section: newsFeb 10, 2026

Pandemic Care Disruptions Linked to Significant Decline in Short-Term Cancer Survival and 17,000 Excess Deaths

Pandemic Care Disruptions Linked to Significant Decline in Short-Term Cancer Survival and 17,000 Excess Deaths

A population-based cohort study using SEER-21 data reveals that patients diagnosed with cancer during 2020 and 2021 experienced significantly lower 1-year cause-specific survival rates compared to prepandemic trends, resulting in an estimat

Section: newsFeb 10, 2026

Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns

Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns

A large-scale federated study of 1.7 million European patients highlights significant variations in cancer survival and comorbidity profiles, emphasizing the role of real-world data and the OMOP-CDM framework in benchmarking oncological out

Section: newsFeb 8, 2026

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk

A massive cohort study of 2.2 million women reveals that ovarian cancer risk factors vary significantly by menopausal status and birth year. While early menarche and low parity remain universal risks, the protective benefits of breastfeedin

Section: newsFeb 6, 2026

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window

A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.

Section: Diabetes & EndocrinologyFeb 5, 2026

The Precision Gap: Evaluating Sentinel Lymph Node Biopsy in Head and Neck Merkel Cell Carcinoma

The Precision Gap: Evaluating Sentinel Lymph Node Biopsy in Head and Neck Merkel Cell Carcinoma

This article examines the clinical accuracy of Sentinel Lymph Node Biopsy for head and neck Merkel cell carcinoma, highlighting a significant false-negative rate and identifying risk factors that necessitate more personalized treatment stra

Section: newsJan 31, 2026

Low-Dose Aspirin and Cancer Mortality in Older Adults: Long-Term ASPREE Results Challenge Previous Paradigms

Low-Dose Aspirin and Cancer Mortality in Older Adults: Long-Term ASPREE Results Challenge Previous Paradigms

A 10-year follow-up of the ASPREE trial reveals that low-dose aspirin does not reduce cancer incidence in adults aged 70 and older, but is associated with increased cancer-related mortality, challenging long-held assumptions about aspirin’s

Section: Internal MedicineJan 30, 2026

Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection

Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection

A massive 21-country study confirms that mammography screening has significantly shifted breast cancer detection toward earlier stages, contributing to a substantial decline in mortality across Europe, though treatment advances also play a

Section: newsJan 29, 2026

Prev 1 2 3 4 5 Next

MedXY News - oncology